Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | USP2 | O75604 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.41 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21991985 | 0.87 | NLRP3 (0.44) | SMN1; SMN2HTTLMNATDP1GAA | |
| SCHEMBL21991998 | 0.87 | HTT (0.43) | SMN1; SMN2HTTLMNATDP1GAA | |
| SCHEMBL21991964 | 0.85 | TSHR (0.51) | SMN1; SMN2HTTLMNATDP1GAA | |
| SCHEMBL21992651 | 0.85 | SMN1; SMN2 (0.47) | SMN1; SMN2HTTLMNATDP1GAA | |
| SCHEMBL21992611 | 0.78 | SMN1; SMN2 (0.48) | SMN1; SMN2HTTLMNATDP1GAA | |
| SCHEMBL24419010 | 0.74 | TSHR (0.48) | SMN1; SMN2HTTLMNATDP1GAA | |
| SCHEMBL21991511 | 0.74 | TSHR (0.47) | SMN1; SMN2HTTLMNATDP1GAA | |
| SCHEMBL21992607 | 0.74 | HTT (0.46) | SMN1; SMN2HTTLMNATDP1GAA | |
| SCHEMBL21991943 | 0.73 | TSHR (0.54) | SMN1; SMN2HTTLMNATDP1GAA | |
| SCHEMBL21991556 | 0.72 | NLRP3 (0.46) | SMN1; SMN2HTTLMNATDP1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220409566-A1 | CCL5 Inhibitors | LAPKO INC, dba AFECTA PHARMACEUTICALS | 2022-12-29 | — | — | US | disclosed |
| US-20220142961-A1 | CCL5 Inhibitors | LAPKO INC, dba AFECTA PHARMACEUTICALS | 2022-05-12 | — | — | US | disclosed |
| US-11318111-B2 | CCL5 inhibitors | LAPKO INC (US) | 2022-05-03 | — | — | US | disclosed |
| US-20210196665-A1 | CCL5 Inhibitors | AFECTA PHARMACEUTICALS, INC. (US) | 2021-07-01 | — | — | US | disclosed |
| US-10940132-B2 | CCL5 inhibitors | AFECTA PHARMACEUTICALS, INC. (US) | 2021-03-09 | — | — | US | disclosed |
| US-20200138766-A1 | CCL5 INHIBITORS | LAPKO INC. DBA AFECTA PHARMACEUTICALS | 2020-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220142961-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | SMN1; SMN2 3122/4885HTT 3640/4885LMNA 4533/4885 |
| US-20200138766-A1 | CCL5 INHIBITORS | CCL5, CCL11, CCR5 | SMN1; SMN2 3122/4885HTT 3640/4885LMNA 4533/4885 |
| US-20210196665-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | SMN1; SMN2 3122/4885HTT 3640/4885LMNA 4533/4885 |
| US-10940132-B2 | CCL5 inhibitors | CCL5, CCL11, CCR5 | SMN1; SMN2 3122/4885HTT 3640/4885LMNA 4533/4885 |
| US-11318111-B2 | CCL5 inhibitors | CCL5, CCL11, CCR5 | SMN1; SMN2 3122/4885HTT 3640/4885LMNA 4533/4885 |
| US-20220409566-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | SMN1; SMN2 3122/4885HTT 3640/4885LMNA 4533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.